Company / Gross Margin
Myriad Genetics, Inc. Gross Margin History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
69.9%
FY2025
5-year range
68.6% / 70.2%
FY2022-FY2025
Trend
+0.1%
vs FY2024
Sector context
#12 of 28
Health Care
What the data says
At 69.9%, Myriad Genetics, Inc.'s gross margin ranks #12 of 28 in the Health Care sector. Gross Margin remained relatively stable over the past 4 years, with values between 68.6% and 70.2%.
Based on SEC 10-K filings.
69.9% in FY2025 with a 3-year CAGR of -0.3%.
Remained stable around 69.9% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -0.3pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#12 of 28 in Health CareTop 43% of 28This company 69.9% Sector average 60.3%
▼
+16.0% above sector average
Key checks
Key Insights
- In FY2025, gross margin increased 0.1% year-over-year.
- Currently 9.6pp above the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 69.9% | +0.1% |
| FY2024 | 69.9% | +1.8% |
| FY2023 | 68.6% | -2.3% |
| FY2022 | 70.2% | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026